Skip to content
Peptide research

Liraglutide

Also known as Saxenda · Victoza
Category
Weight Management & Metabolic
Administration routes
Injectable
Regulatory status
FDA-approved

Liraglutide is a GLP-1 receptor agonist marketed for type 2 diabetes and weight loss. Human evidence here is genuinely strong, backed by large trials showing glycemic control, weight loss, and cardiovascular risk reduction. Tradeoffs include common GI side effects, gallbladder and pancreatitis risk, and a boxed thyroid tumor warning barring those with medullary thyroid cancer history. It is FDA-approved (Saxenda, Victoza), not a gray-market peptide.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Liraglutide is a lab-made version of GLP-1, a natural hormone your body releases after eating to signal fullness. Sold under the brand names Victoza (for type 2 diabetes) and Saxenda (for weight management), it is 97% identical to the natural hormone but engineered with a fatty acid chain that lets it bind to blood proteins and last about 13 hours per dose instead of minutes. Developed by Novo Nordisk, liraglutide is FDA-approved for type 2 diabetes, chronic weight management, and reducing cardiovascular risk. It works by boosting insulin release when blood sugar is high, suppressing inappropriate glucagon, slowing stomach emptying, and acting on appetite centers in the brain. As of 2025, generic liraglutide is available in the US, making it the first generic GLP-1 drug on the market.

How it works in the body

A GLP-1 receptor agonist with 97% amino acid similarity to natural GLP-1. A fatty acid side chain allows it to bind albumin, extending its half-life to 13 hours. It activates GLP-1 receptors on pancreatic beta cells (boosting insulin), brain appetite centers (reducing hunger), and cardiac cells (providing cardioprotection).

Research overview

Liraglutide is one of the most extensively studied GLP-1 receptor agonists, backed by over 15 years of clinical trial data and real-world use. The LEAD program (6 Phase 3 trials) established its diabetes efficacy. The landmark LEADER trial — one of the largest cardiovascular outcomes studies ever conducted for a diabetes drug — followed 9,340 high-risk patients for a median of 3.8 years and showed a 13% reduction in major heart events and a 22% reduction in cardiovascular death. For weight loss, the SCALE Obesity trial (3,731 patients) demonstrated an average body weight reduction of 8% (about 8.4 kg / 18.5 lbs) over 56 weeks at the 3.0 mg dose. Liraglutide also showed kidney-protective effects, with a 22% reduction in new or worsening kidney disease. The evidence base for liraglutide is among the strongest for any peptide therapy, with large, well-designed randomized controlled trials across multiple indications.

Who researches Liraglutide?

Commonly researched by

  • People researching weight management options

    Studied for effects on body composition, appetite regulation, or metabolic rate.

  • People researching cardiovascular health

    Studied for effects on heart function, blood pressure, or vascular health.

  • People researching blood sugar regulation

    Studied for effects on insulin sensitivity, glucose metabolism, or glycemic control.

  • People researching kidney and renal health

    Studied for renal protective or nephroprotective effects.

Important considerations for

  • Those with Personal/family history of MTC

    Absolute

    FDA boxed warning: thyroid C-cell tumors in rodents. Contraindicated in MTC or MEN2 syndrome.

  • Those with History of pancreatitis

    High

    Post-marketing cases of acute pancreatitis including fatal hemorrhagic pancreatitis reported.

  • Those with Severe gastroparesis

    High

    Slows gastric emptying. Patients with gastroparesis excluded from clinical trials.

  • Those with Severe renal impairment

    Moderate

    GI side effects may cause dehydration and acute kidney injury. Monitor renal function.

  • Those who are pregnant or breastfeeding

    Absolute

    Discontinue at least 2 months before planned conception. Animal data shows fetal harm.

Safety & interactions

Do not use if

  • Personal/family history of MTC

    Absolute

    FDA boxed warning: thyroid C-cell tumors in rodents. Contraindicated in MTC or MEN2 syndrome.

  • History of pancreatitis

    High

    Post-marketing cases of acute pancreatitis including fatal hemorrhagic pancreatitis reported.

  • Severe gastroparesis

    High

    Slows gastric emptying. Patients with gastroparesis excluded from clinical trials.

  • Severe renal impairment

    Moderate

    GI side effects may cause dehydration and acute kidney injury. Monitor renal function.

General cautions

  • Pregnancy

    Absolute

    Animal studies indicate potential fetal harm. Discontinue Saxenda when pregnancy is recognized. FDA labeling does not specify a two-month preconception interval for liraglutide.

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(10)

Rated by level of concern

  • GI side effects: nausea, diarrhea, vomiting, decreased appetite, constipation (most common, affecting 20-40%)

    High

    Saxenda FDA label §6.1 Adverse Reactions, DailyMed setid 3946d389-0926-4f77-a708-0acb8153b143 (rates confirmed against the live label)

  • Hypoglycemia risk when combined with insulin or sulfonylureas; dose reduction of co-administered agents may be needed

    High

    Victoza FDA label §5.4 and §7.2 (DailyMed); PMID 27295427 (LEADER)

  • Gallbladder disease: cholelithiasis occurred in 2.2% versus 0.8% with placebo in Saxenda adult trials; cholecystitis occurred in 0.8% versus 0.4%. LEADER acute gallbladder events were 3.1% versus 1.9%.

    Moderate

    Saxenda FDA label §5.3 Acute Gallbladder Disease and §6.1 (DailyMed); Victoza FDA label §5.8; PMID 27295427 (LEADER)

  • Elevated resting heart rate: 4-9 bpm increase; reports of tachycardia >100 bpm

    Moderate

    Saxenda FDA label §5.5 Heart Rate Increase (DailyMed: mean increases of 2 to 3 beats per minute); Victoza FDA label §6.1 (same 2-3 bpm figure); PMID 23355666 (Robinson LE et al, BMJ Open 2013)

  • Boxed warning: thyroid C-cell tumors in rodent studies at clinically relevant doses; contraindicated in MTC/MEN 2 patients

    Moderate

    Victoza and Saxenda FDA labels, Boxed Warning and §5.1 Risk of Thyroid C-cell Tumors (DailyMed)

  • Acute pancreatitis risk (<0.4% of patients); discontinue if suspected

    Moderate

    Victoza FDA label §5.2 (DailyMed); PMID 27295427 (LEADER)

  • Acute kidney injury: postmarketing reports, usually secondary to dehydration from GI effects

    Low

    Victoza FDA label §5.5 (DailyMed); PMID 28854085 (Mann JFE et al, NEJM 2017)

  • Historical reports of suicidal behavior and ideation prompted review, but FDA found no increased risk and the Saxenda warning was removed in February 2026.

    Theoretical

    Saxenda clinical trial data as reported in prior FDA labeling (current DailyMed label verified as no longer carrying this Warnings and Precautions section); FDA Drug Safety Communication, preliminary evaluation of suicidal thoughts with GLP-1 RAs (January 2024); EMA PRAC review conclusion (April 2024)

  • Hypersensitivity reactions: anaphylaxis and angioedema reported (rare)

    Low

    Victoza FDA label §5.7 and §6.2 (DailyMed)

  • Injection site reactions: erythema, pruritus, nodule formation

    Low

    Saxenda FDA label §6.1 (DailyMed)

Interaction summary(8)

Rated by direction with this peptide

  • Insulin (basal or prandial)

    CautionHigh

    Adding liraglutide to insulin raises the risk of severe hypoglycemia. The label directs that insulin dose reduction may be necessary at initiation, with titration back up under glucose monitoring.

    Victoza FDA label §5.4 Hypoglycemia and §7.2 Concomitant Use with an Insulin Secretagogue or Insulin (DailyMed setid 5a9ef4ea-c76a-4d34-a604-27c5b505f5a4)

  • Sulfonylureas (glimepiride, glipizide, glyburide)

    CautionHigh

    Sulfonylurea-driven insulin secretion is not glucose-dependent, so combination with liraglutide produced clearly increased hypoglycemia in the LEAD trials and LEADER; a pre-emptive sulfonylurea dose reduction is recommended.

    PMID 27295427 (LEADER, NEJM 2016); Victoza FDA label §7.2 (DailyMed)

  • Other GLP-1 receptor agonists (semaglutide, dulaglutide, tirzepatide)

    CautionModerate

    Coadministration with another GLP-1 receptor agonist is not recommended per the labels' Limitations of Use - the incretin pathway is already saturated, so there is no added efficacy but additive GI toxicity. DPP-4 inhibitors (sitagliptin and others) were split out of this entry: their exclusion rests on guideline and mechanistic-redundancy reasoning rather than a labeled interaction, and coadministration is low-value rather than hazardous.

    Saxenda and Victoza FDA labels, §1 Limitations of Use (DailyMed); ADA Standards of Care, Pharmacologic Approaches to Glycemic Treatment (basis for the DPP-4 redundancy point)

  • General anesthesia and procedural sedation (elective surgery, endoscopy)

    CautionModerate

    Labeled warning: Victoza §5.9 / Saxenda §5.9, 'Pulmonary Aspiration During General Anesthesia or Deep Sedation'. Delayed gastric emptying can leave retained gastric contents despite standard fasting. The 2023 ASA advice to hold daily agents on the day of the procedure has been superseded by the 2024 multisociety (ASA/AGA/ASGE/ISAS/SAGES) guidance, which does NOT recommend routine cessation for most patients and instead advises a 24-hour clear-liquid diet before the procedure, individualized risk assessment, and consideration of point-of-care gastric ultrasound or full-stomach precautions.

    Victoza/Saxenda FDA label §5.9 (DailyMed); ASA consensus-based guidance 2023, superseded by the 2024 multisociety clinical practice guidance on perioperative management of GLP-1 receptor agonists

  • Orally administered drugs generally, including narrow-therapeutic-index agents (levothyroxine, warfarin, oral contraceptives)

    CautionLow

    Liraglutide delays gastric emptying and can shift absorption: dedicated PK studies found oral contraceptive Tmax delayed ~1.5 h, digoxin AUC -16%, lisinopril AUC -15%, with no changes judged clinically relevant. Correction: the Victoza label contains NO warfarin- or INR-specific statement (checked against the live label). INR and thyroid-function monitoring on initiation or titration is prudent clinical practice extrapolated from the gastric-emptying mechanism and from other GLP-1 RA labels, not a labeled liraglutide instruction. The interactant name was broadened accordingly.

    Victoza FDA label §7.1 Effects of Delayed Gastric Emptying on Oral Medications and §12.3 Pharmacokinetics (DailyMed; no warfarin/INR text present)

  • Diuretics, ACE inhibitors/ARBs and other antihypertensives

    CautionLow

    No pharmacokinetic interaction - this entry is mechanistic and label-implied only. Volume depletion from liraglutide-induced nausea, vomiting or diarrhea can compound diuretic/RAAS-blockade effects and precipitate hypotension or prerenal acute kidney injury; hold or reduce diuretics during significant GI illness. Additive blood-pressure lowering is also expected given liraglutide's ~2-4 mmHg systolic effect.

    Victoza FDA label §5.5 Acute Kidney Injury Due to Volume Depletion (DailyMed)

  • Metformin

    SynergisticLow

    No pharmacokinetic interaction and complementary mechanisms (hepatic glucose output vs incretin-mediated insulin secretion and satiety); the combination is a standard, RCT-validated regimen with additive HbA1c and weight benefit and no added hypoglycemia.

    PMID 19515413 (LEAD-6, Lancet 2009 - metformin/sulfonylurea background therapy); Victoza FDA label §7 and §12.3 (DailyMed)

  • SGLT2 inhibitors (empagliflozin, dapagliflozin)

    SynergisticLow

    Distinct mechanisms give additive glycemic, weight and blood-pressure effects with no known pharmacokinetic interaction; watch cumulative volume depletion in patients with GI intolerance. Additive cardiorenal outcome benefit from the combination has not been tested in a dedicated outcome trial - it is inferred from the separate trial programs.

    ADA Standards of Care, Pharmacologic Approaches to Glycemic Treatment.

Known risks(10)

  • Boxed warning: thyroid C-cell tumors in rodent studies at clinically relevant doses; contraindicated in MTC/MEN 2 patients

  • GI side effects: nausea, diarrhea, vomiting, decreased appetite, constipation (most common, affecting 20-40%)

  • Acute pancreatitis risk (<0.4% of patients); discontinue if suspected

  • Gallbladder disease: Saxenda adult trials reported cholelithiasis in 2.2% versus 0.8% with placebo, and cholecystitis in 0.8% versus 0.4%. LEADER reported acute gallbladder events in 3.1% versus 1.9%.

  • Elevated resting heart rate: 4-9 bpm increase; reports of tachycardia >100 bpm

  • Hypoglycemia risk when combined with insulin or sulfonylureas; dose reduction of co-administered agents may be needed

  • Acute kidney injury: postmarketing reports, usually secondary to dehydration from GI effects

  • FDA's completed review found no increased risk of suicidal behavior or ideation with GLP-1 receptor agonists. FDA requested removal of this warning in January 2026, and Saxenda labeling removed it in February 2026. Historical trial reports do not establish a drug-caused risk.

  • Hypersensitivity reactions: anaphylaxis and angioedema reported (rare)

  • Injection site reactions: erythema, pruritus, nodule formation

Drug interactions(9)

  • Insulin

    Enhanced hypoglycemic effect. No pharmacokinetic interaction but additive glucose-lowering. Insulin dose reduction recommended when initiating liraglutide.

  • Sulfonylureas

    Increased hypoglycemia risk. Consider reducing sulfonylurea dose when starting liraglutide.

  • Oral medications (general)

    Liraglutide slows gastric emptying, potentially delaying absorption of co-administered oral drugs. Take time-sensitive oral medications 1+ hour before liraglutide injection.

  • Digoxin

    AUC reduced 16%, Cmax reduced 31%. Monitor digoxin levels and clinical response.

  • Atorvastatin

    Cmax reduced 38% due to delayed gastric emptying. Overall AUC not significantly affected. No dose adjustment typically needed but monitor lipid levels.

  • Lisinopril

    AUC reduced 15%, Cmax reduced 27%. Monitor blood pressure control.

  • Acetaminophen

    Cmax reduced 31%. Onset of effect may be delayed. Clinical significance usually minimal.

  • Oral contraceptives

    Cmax reduced ~12% for ethinyl estradiol and levonorgestrel components. Consider backup contraception or non-oral formulations.

  • Other GLP-1 agonists (semaglutide, tirzepatide)

    Overlapping mechanism. Combining would increase GI side effects and hypoglycemia risk without additional benefit.

Research & benefits

Evidence base

Evidence Level
Level 1 — Strong
Total Studies
150
Human Studies
149

Over 25,000 participants across Phase 3 programs (LEAD, SCALE, LEADER). Strong evidence for glycemic control, weight loss, CV risk reduction, and renal protection. 9,340-patient LEADER CVOT with 3.8-year follow-up is the cornerstone trial.

Researched for(7)

Rated by confidence in the evidence

  • Type 2 diabetes glycemic control

    High

    Large phase 3 trials showed HbA1c reductions of about 1 to 1.5 percentage points.

    PMID 19515413 (Buse JB et al, LEAD-6, Lancet 2009); Victoza FDA label, Indications and §14 Clinical Studies, DailyMed setid 5a9ef4ea-c76a-4d34-a604-27c5b505f5a4

  • Significant weight loss

    High

    Large 56-week trial showed average weight loss of 8.4 kg versus 2.8 kg with placebo.

    PMID 26132939 (Pi-Sunyer X et al, NEJM 2015;373:11-22)

  • Cardiovascular risk reduction

    High

    Large cardiovascular outcomes trial in high-risk type 2 diabetes patients showed reduced major cardiac events.

    PMID 27295427 (Marso SP et al, NEJM 2016;375:311-322)

  • Renal protection

    Medium

    Secondary trial data found fewer kidney complications, driven mainly by reduced urine protein levels.

    PMID 28854085 (Mann JFE et al, NEJM 2017;377:839-848)

  • Prediabetes regression

    High

    Three-year trial showed fewer diabetes diagnoses and more reversal to normal blood sugar on treatment.

    PMID 28237263 (le Roux CW et al, Lancet 2017;389:1399-1409)

  • Cardiometabolic risk factor improvement

    Medium

    Trial data support modest blood pressure and waist reduction; other metabolic marker effects are less established.

    PMID 26132939 (SCALE, NEJM 2015); PMID 23355666 (Robinson LE et al, BMJ Open 2013 - supports the BP/heart-rate/weight components only; does NOT support the hs-CRP, triglyceride or HOMA-IR components)

  • Beta-cell preservation

    Low

    Small human trial and animal data suggest a temporary effect, not durable beta-cell preservation.

    PMID 25249651 (Retnakaran R et al, LIBRA trial, Diabetes Care 2014;37:3270-3278)

Benefits(7)

  • Type 2 diabetes glycemic control

  • Significant weight loss

  • Cardiovascular risk reduction

  • Renal protection

  • Prediabetes regression

  • Cardiometabolic risk factor improvement

  • Beta-cell preservation

Key studies(6)

  1. Marso SP et al.

    NEJM

    2016

    13% MACE reduction (HR 0.87, 95% CI 0.78-0.97, p=0.01); 22% CV death reduction; 15% all-cause mortality reduction

  2. Pi-Sunyer X et al.

    NEJM

    2015

    Mean weight loss of 8.0% (8.4 kg) vs 2.6% placebo; 63.2% achieved ≥5% weight loss vs 27.1% placebo

  3. Davies MJ et al.

    JAMA

    2015

    54.3% achieved ≥5% weight loss with 3.0 mg vs 21.4% placebo; HbA1c reduction of 1.3% vs 0.3%

  4. Garber A et al.

    Lancet

    2009

    HbA1c reduction of 1.14% with 1.8 mg; superior to glimepiride with less hypoglycemia and weight loss vs weight gain

  5. Mann JFE et al.

    NEJM

    2017

    22% reduction in new or worsening nephropathy (HR 0.78); primarily driven by reduction in new-onset macroalbuminuria

  6. Kelly AS et al.

    NEJM

    2020

    The between-group difference in change in BMI SDS at week 56 was −0.22 in favor of liraglutide (95% CI −0.37 to −0.08; p=0.002), a significant weight-management benefit in adolescents.

What research suggests over time

  • Weeks 2-4

    SCALE / LEAD trials

    Reduced appetite and food cravings as the dose is titrated toward target; early A1c improvements in T2DM.

  • Months 2-3

    Phase 3 RCT

    ~5-7% weight loss with Saxenda as the dose is titrated up; HbA1c reduction of 1.0-1.5% in T2DM with Victoza.

  • Long-term

    Phase 3 CVOT

    Mean 8.0% weight loss at 56 weeks (SCALE Obesity NEJM 2015); 13% MACE reduction and 22% CV death reduction over 3.8 years (LEADER CVOT NEJM 2016).

Prescribing labels

FDA-Approved Labels

This page does not list doses. Each product below has an FDA label with its prescribing information.

Protocol
Victoza (liraglutide)
Notes
Dosing is set by your prescriber and the FDA label.
Protocol
Saxenda (liraglutide)
Notes
Dosing is set by your prescriber and the FDA label.

Monitoring & labs

Baseline before starting, then per marker schedule during protocol.

Baseline labs(8)

  • Complete Blood Count (CBC)

    Optimal All markers within mid-range

    Establishes baseline for detecting hematological changes.

    Lab normal Standard reference ranges

  • Comprehensive Metabolic Panel (CMP)

    Optimal Liver enzymes <25, glucose 75–90, eGFR >90

    Liver and kidney function baseline.

    Lab normal Standard reference ranges

  • Fasting glucose + HbA1c

    Optimal 75–90 mg/dL

    Baseline metabolic markers — critical for tracking glucose regulation changes.

    Lab normal 65–99 mg/dL

  • Lipid panel

    Optimal ApoB <80, TG <80, HDL >55

    Cholesterol and triglyceride baseline for tracking cardiovascular metabolic effects.

    Lab normal TC <200, LDL <100, HDL >40, TG <150

  • Thyroid panel (TSH, free T3/T4)

    Optimal TSH 1.0–2.0; Free T3 upper third of range

    Thyroid function can be affected by metabolic peptides.

    Lab normal TSH 0.4–4.5

  • Amylase + Lipase

    Optimal Both within mid-range

    Baseline pancreatic markers — this peptide carries a documented pancreatitis risk.

    Lab normal Standard ranges

  • Calcitonin

    Optimal Under 5 pg/mL

    Baseline thyroid C-cell marker — thyroid C-cell tumor risk documented.

    Lab normal Under 10 pg/mL (men)

  • Blood pressure + heart rate

    Cardiovascular baseline — tachycardia risk documented.

Ongoing tracking(6)

  • Fasting glucose + HbA1c

    Every 4-8 weeksOptimal 75–90 mg/dL

    Track glucose regulation changes during protocol.

    Lab normal 65–99 mg/dL

  • Lipid panel

    Every 8-12 weeksOptimal ApoB <80, TG <80, HDL >55

    Monitor cholesterol and triglyceride response.

    Lab normal TC <200, LDL <100, HDL >40, TG <150

  • Liver enzymes (ALT/AST)

    Every 8 weeksOptimal ALT & AST under 25 U/L

    Hepatic function monitoring during metabolic modulation.

    Lab normal ALT 7–56, AST 10–40 U/L

  • Amylase + Lipase

    Every 8-12 weeksOptimal Both within mid-range

    Pancreatic enzyme monitoring — pancreatitis risk.

    Lab normal Standard ranges

  • Calcitonin

    Every 12 weeksOptimal Under 5 pg/mL

    Thyroid C-cell monitoring.

    Lab normal Under 10 pg/mL (men)

  • Blood pressure + heart rate

    Every 4 weeks

    Cardiovascular monitoring — tachycardia risk.

Retest schedule(6)

  1. Baseline

    critical

    Before starting

    Full baseline + thyroid panel, lipase, amylase, HbA1c, lipid panel.

  2. Early follow-up

    critical

    Week 4

    Recheck lipase, amylase, glucose. Most early-protocol concerns surface here.

  3. Second check

    critical

    Week 8

    Recheck metabolic markers and GI tolerance.

  4. Mid-protocol

    critical

    Week 12

    Comprehensive retest. Track HbA1c, weight, lipids, thyroid.

  5. Ongoing

    standard

    Every 12 weeks

    Sustained metabolic monitoring during chronic use.

  6. Post-protocol

    standard

    4-6 weeks after stopping

    Track for weight regain and metabolic rebound.

When to stop and reassess(7)

  • ALT or AST

    stop

    Above 2× upper limit of normal (>~80 U/L)

    Stop protocol and consult a provider — possible drug-induced liver injury.

  • eGFR

    stop

    Drop of >15 mL/min/1.73m² from baseline, or below 60

    Stop protocol and consult a provider — possible kidney function decline.

  • Symptoms

    stop

    New severe symptoms correlating with lab changes

    Stop protocol and seek medical evaluation immediately.

  • Lipase or amylase

    stop

    Above 3× upper limit of normal

    Stop protocol and seek urgent medical evaluation — possible pancreatitis.

  • Calcitonin

    consult

    Above 10 pg/mL or rising trend

    Consult an endocrinologist — possible thyroid C-cell stimulation.

  • Heart rate

    consult

    Sustained >100 bpm or new palpitations

    Consult a provider — GLP-1 agonists can affect cardiac rhythm.

  • Lipase

    stop

    Above 3× upper limit of normal

    Stop protocol and seek urgent medical evaluation — pancreatitis risk documented.

Lab monitoring helps track your body's response to Liraglutide. Any unexplained changes should prompt discussion with your prescribing provider.

Regulation & availability

Why researchers look at it

The LEADER trial — 9,340 high-risk patients followed for nearly four years — showed a 13% reduction in major cardiovascular events and 22% reduction in cardiovascular death, the first evidence that a GLP-1 drug could protect the heart. The SCALE program (3,731 patients) demonstrated ~8% sustained weight loss at the Saxenda dose. While newer weekly GLP-1s like semaglutide have surpassed it in efficacy, liraglutide became the first generic GLP-1 on the US market in 2024-2025, making it the most affordable entry point into this drug class.

Estimated cost
$1,000-1,400/mo retail (Victoza/Saxenda); insurance may cover for diabetes
FDA status
FDA-approved. Victoza approved January 2010 for T2DM in adults (expanded to age 10+ in 2019). Saxenda approved December 2014 for adult weight management (expanded to age 12+ in 2020). Carries boxed warning for thyroid C-cell tumor risk based on rodent studies. Teva launched an authorized generic of Victoza in June 2024; FDA approved Hikma's generic Victoza on December 23, 2024 and Teva's generic Saxenda on August 27, 2025. Pancreatitis and gallbladder warnings remain. FDA found no increased risk of suicidal behavior or ideation, requested warning removal in January 2026, and Saxenda labeling removed it in February 2026.
WADA status
Liraglutide is not prohibited under WADA's 2026 Prohibited List and is not specifically included in the 2026 Monitoring Program. That program monitors markers of semaglutide and tirzepatide in and out of competition. Monitoring those substances does not extend automatically to every GLP-1 receptor agonist.
Prescribability
Yes — prescription required. FDA-approved as Victoza (T2DM) and Saxenda (weight management). Generic versions available from Teva (2024 for diabetes, 2025 for weight loss).
Availability
Available by prescription as Victoza (for type 2 diabetes), Saxenda (for weight management), and generic liraglutide, with supply varying by product and country. FDA currently lists liraglutide injection as in shortage: branded Victoza and Saxenda have limited availability, while several generic presentations are listed as available. FDA reports planned US Saxenda discontinuation in January 2027. Teva launched an authorized generic of Victoza in June 2024; Hikma received a generic Victoza ANDA approval in December 2024, and Teva's generic Saxenda was approved in August 2025. Clinics and compounding pharmacies may offer liraglutide, subject to applicable compounding requirements; compounded versions are not FDA-approved. Administration is by subcutaneous injection using a pen.

International status

  • EU

    EMA-approved

  • UK

    MHRA-approved

  • US

    FDA-approved (Victoza, Saxenda)

  • Canada

    Health Canada-approved

  • Australia

    TGA-approved

Regulatory timeline(7)

  1. 2010-01
    Victoza FDA approvalApproved for T2DM glycemic control in adults as adjunct to diet/exercise
  2. 2014-12
    Saxenda FDA approvalApproved for chronic weight management in adults with BMI ≥30 or ≥27 with comorbidity
  3. 2017-08
    LEADER CV indication addedVictoza label expanded to include CV risk reduction based on LEADER trial results
  4. 2019-06
    Pediatric T2DM expansionVictoza approved for patients age 10+ with T2DM
  5. 2020-12
    Pediatric obesity expansionSaxenda approved for patients aged 12 and older with body weight greater than 60 kg and obesity defined by pediatric age- and sex-specific criteria corresponding to an adult BMI of at least 30.
  6. 2024
    Generic Victoza approvedTeva launched an authorized generic of Victoza in June 2024. FDA approved Hikma's generic Victoza ANDA on December 23, 2024, its first separately approved generic of once-daily liraglutide.
  7. 2025-08
    Generic Saxenda approvedTeva generic liraglutide for weight management — first generic GLP-1 for weight loss in the US

Sources & FAQs

Research sources(7)

Frequently asked questions(6)

What is the difference between Victoza and Saxenda?

Both contain liraglutide but at different doses for different indications. Victoza is for type 2 diabetes glycemic control. Saxenda, at a higher dose, is for chronic weight management. They should not be used together. Dosing is set by your prescriber and the FDA label.

What are the most common side effects?

GI effects are most common: nausea, diarrhea, vomiting, decreased appetite, dyspepsia, and constipation. These typically diminish over 4-8 weeks as the body adjusts. Serious but rare effects include pancreatitis (<0.4%), gallbladder disease (2.2%), and elevated heart rate (4-9 bpm increase).

Who should NOT take liraglutide?

Contraindicated in people with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Not for type 1 diabetes or diabetic ketoacidosis. Caution in patients with a history of pancreatitis or severe GI disease. FDA found no increased risk of suicidal behavior or ideation with GLP-1 receptor agonists, and the Saxenda warning was removed in February 2026.

How much weight can I expect to lose?

In the SCALE trial, average weight loss was 8.0% of body weight (about 8.4 kg / 18.5 lbs) over 56 weeks at the Saxenda dose. About 63% of participants lost ≥5% and 33% lost ≥10% of body weight. Individual results vary significantly.

How does liraglutide compare to semaglutide?

Semaglutide generally produces greater weight loss (15-17% vs 8%) and has weekly dosing convenience vs daily for liraglutide. However, liraglutide has a longer safety track record (approved 2010 vs 2017), a lower starting cost with generics now available, and similar cardiovascular benefits. Liraglutide may suit patients who prefer gradual dose titration.

Is a generic version available?

Yes. Teva Pharmaceuticals launched generic liraglutide for T2DM in 2024 and for weight management in August 2025. It is the first generic GLP-1 receptor agonist available in the US, offering a more affordable alternative to branded Victoza and Saxenda.